维立志博-B再涨超6% 维利信获欧盟孤儿药资格及美国FDA快速通道资格认定

智通财经
Jan 27

维立志博-B(09887)再涨超6%,截至发稿,涨5.07%,报62.2港元,成交额2440.12万港元。消息面上,维立志博1月22日宣布,核心产品维利信(LBL-024)获欧盟委员会授予的孤儿药资格认定,用于治疗肺外神经内分泌癌(EP-NEC)。这是维利信全球开发进程中又一个重要里程碑,目前,维利信已在非小细胞肺癌(NSCLC)、小细胞肺癌(SCLC)和EP-NEC三个适应症的二期或注册性...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10